The CMS decision to open a national coverage analysis for Dendreon's autologous cellular immunotherapy Provenge appears to be motivated by the cost of the product and could have a chilling effect on innovation, Biotechnology Industry Organization CEO Jim Greenwood said. During an Aug. 18 meeting with "The Pink Sheet" DAILY editorial staff, Greenwood took aim at the Provenge NCA. CMS announced the NCA June 30, soon after FDA approved the product for the treatment of asymptomatic and hormone refractory...